A Phase II multicenter, placebo-controlled, proof-of-concept study evaluating the safety, and efficacy of intratympanic STR001 thermogel to preserve residual hearing in adults undergoing cochlear implant surgery

Trial Profile

A Phase II multicenter, placebo-controlled, proof-of-concept study evaluating the safety, and efficacy of intratympanic STR001 thermogel to preserve residual hearing in adults undergoing cochlear implant surgery

Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Feb 2017

At a glance

  • Drugs Pioglitazone (Primary)
  • Indications Hearing loss
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Strekin
  • Most Recent Events

    • 15 Feb 2017 Accrding to Strekin media release, as of 10 Feb 2017 this trial has enrolled 50 patients in four countries and top-line data is expected in the Q4 quarter of 2017.
    • 25 Nov 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top